Food Allergy Diagnostic Testing Is Unreliable, Causing Over-Restriction

The standard diagnostic tools for food allergies — skin prick tests (SPT) and serum-specific IgE blood tests — have high false-positive rates, often exceeding 50%. A positive SPT or elevated IgE level indicates sensitization (the immune system recognizes the protein) but does not reliably predict clinical allergy (the immune system will cause a dangerous reaction upon ingestion). The gold standard for diagnosis is the oral food challenge (OFC), in which a patient eats incrementally increasing doses of the suspected allergen under medical supervision. But OFCs are time-consuming (3-6 hours), require specialized staff and emergency equipment, and are underused. A 2019 JACI study estimated that fewer than 5% of allergist practices in the U.S. perform OFCs regularly. The consequence is massive over-diagnosis. Studies suggest that while approximately 10% of U.S. adults have a true food allergy (confirmed by history and/or OFC), nearly 19% believe they are allergic. Many of these individuals were told by a doctor — based on a skin test or blood test alone — that they are allergic to a food they can actually eat safely. They then spend years or decades avoiding that food unnecessarily, limiting their nutrition, social participation, and quality of life. For children, the impact is compounded. Parents receive a positive test result, eliminate the food, and the child grows up never eating it. The irony is that early introduction of allergens (as shown by the LEAP trial for peanuts) can prevent allergy development. A false-positive test that leads to avoidance may actually increase the likelihood that a child develops a true allergy over time, turning a diagnostic error into a self-fulfilling prophecy. This problem persists because the economic incentives favor testing over challenging. A skin prick panel takes 20 minutes and bills at $150-$400. An oral food challenge requires 3-6 hours of physician and nursing time, carries real (though small) risk, and bills at a rate that barely covers the staff cost. Allergist practices performing OFCs face lower throughput and higher liability. Insurance reimbursement for OFCs is inconsistent, and many plans require prior authorization, creating administrative barriers. The structural root cause is a diagnostic paradigm built on convenience rather than accuracy. SPT and IgE testing were developed as screening tools to be followed by confirmatory OFCs, but in practice the screening test became the final diagnosis. Reforming this requires changing how allergists are trained, how they are reimbursed, and how patients understand the difference between sensitization and allergy — a distinction that most doctors outside of allergy subspecialty do not clearly communicate.